NO328062B1 - Fremgangsmate for fremstilling av agglomerater - Google Patents

Fremgangsmate for fremstilling av agglomerater Download PDF

Info

Publication number: NO328062B1
Authority: NO; Norway
Prior art keywords: agglomerates; particles; solid binder; convertible; drug
Prior art date: 1997-03-20

Application number

NO19994519A

Other languages

English (en)

Norwegian (no)

Other versions

NO994519D0 (no

NO994519L (no

Inventor

Tsong-Toh Yang

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-20

Filing date

1999-09-17

Publication date

2009-11-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25232603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO328062(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-09-17 Application filed by Schering Corp filed Critical Schering Corp

1999-09-17 Publication of NO994519D0 publication Critical patent/NO994519D0/no

1999-11-19 Publication of NO994519L publication Critical patent/NO994519L/no

2009-11-13 Publication of NO328062B1 publication Critical patent/NO328062B1/no

Links

238000004519 manufacturing process Methods 0.000 title claims description 14
239000011230 binding agent Substances 0.000 claims description 101
239000002245 particle Substances 0.000 claims description 97
239000000463 material Substances 0.000 claims description 90
239000007787 solid Substances 0.000 claims description 65
238000000034 method Methods 0.000 claims description 55
239000013543 active substance Substances 0.000 claims description 42
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 30
238000005054 agglomeration Methods 0.000 claims description 25
230000002776 aggregation Effects 0.000 claims description 25
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 20
229960001375 lactose Drugs 0.000 claims description 19
239000008101 lactose Substances 0.000 claims description 19
238000006243 chemical reaction Methods 0.000 claims description 17
229960002744 mometasone furoate Drugs 0.000 claims description 15
WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 15
229960004977 anhydrous lactose Drugs 0.000 claims description 12
238000009826 distribution Methods 0.000 claims description 10
230000008569 process Effects 0.000 claims description 9
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 5
229960002052 salbutamol Drugs 0.000 claims description 5
238000002425 crystallisation Methods 0.000 claims description 4
230000008025 crystallization Effects 0.000 claims description 4
229960002848 formoterol Drugs 0.000 claims description 4
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
239000000556 agonist Substances 0.000 claims description 3
150000001299 aldehydes Chemical class 0.000 claims description 3
150000001413 amino acids Chemical class 0.000 claims description 3
239000003246 corticosteroid Substances 0.000 claims description 3
150000002576 ketones Chemical class 0.000 claims description 3
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 2
PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 claims description 2
LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims description 2
KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
102000004877 Insulin Human genes 0.000 claims description 2
108090001061 Insulin Proteins 0.000 claims description 2
102000014150 Interferons Human genes 0.000 claims description 2
108010050904 Interferons Proteins 0.000 claims description 2
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 2
YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 2
HEUMNKZPHGRBKR-UHFFFAOYSA-N [Na].[Cr] Chemical compound [Na].[Cr] HEUMNKZPHGRBKR-UHFFFAOYSA-N 0.000 claims description 2
229960003060 bambuterol Drugs 0.000 claims description 2
ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 claims description 2
229950000210 beclometasone dipropionate Drugs 0.000 claims description 2
229960004620 bitolterol Drugs 0.000 claims description 2
FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 claims description 2
JBRBWHCVRGURBA-UHFFFAOYSA-N broxaterol Chemical compound CC(C)(C)NCC(O)C1=CC(Br)=NO1 JBRBWHCVRGURBA-UHFFFAOYSA-N 0.000 claims description 2
229950008847 broxaterol Drugs 0.000 claims description 2
150000001720 carbohydrates Chemical class 0.000 claims description 2
239000000812 cholinergic antagonist Substances 0.000 claims description 2
229960001117 clenbuterol Drugs 0.000 claims description 2
STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims description 2
229960001334 corticosteroids Drugs 0.000 claims description 2
229960003957 dexamethasone Drugs 0.000 claims description 2
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
229960001022 fenoterol Drugs 0.000 claims description 2
229960000676 flunisolide Drugs 0.000 claims description 2
229960002714 fluticasone Drugs 0.000 claims description 2
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
229940047135 glycate Drugs 0.000 claims description 2
229940125396 insulin Drugs 0.000 claims description 2
229940047124 interferons Drugs 0.000 claims description 2
229960001361 ipratropium bromide Drugs 0.000 claims description 2
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 2
239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
229960002259 nedocromil sodium Drugs 0.000 claims description 2
229960001609 oxitropium bromide Drugs 0.000 claims description 2
LCELQERNWLBPSY-KHSTUMNDSA-M oxitropium bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CC)=CC=CC=C1 LCELQERNWLBPSY-KHSTUMNDSA-M 0.000 claims description 2
239000000199 parathyroid hormone Substances 0.000 claims description 2
229960002288 procaterol Drugs 0.000 claims description 2
FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 claims description 2
108090000765 processed proteins & peptides Proteins 0.000 claims description 2
102000004169 proteins and genes Human genes 0.000 claims description 2
108090000623 proteins and genes Proteins 0.000 claims description 2
MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
229960004017 salmeterol Drugs 0.000 claims description 2
229960000195 terbutaline Drugs 0.000 claims description 2
229960005294 triamcinolone Drugs 0.000 claims description 2
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
229960004764 zafirlukast Drugs 0.000 claims description 2
VMLIIHQLCPMIAT-KQLJPZFVSA-N (4r,8'r,9's,10'r,13's,14's)-10',13'-dimethyl-2-propylspiro[1,3-dioxane-4,17'-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene]-3',5-dione Chemical compound O1C(CCC)OCC(=O)[C@@]11[C@@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4CC[C@H]3[C@@H]2CC1 VMLIIHQLCPMIAT-KQLJPZFVSA-N 0.000 claims 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
229960004436 budesonide Drugs 0.000 claims 1
229960004583 pranlukast Drugs 0.000 claims 1
UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 claims 1
239000003814 drug Substances 0.000 description 109
229940079593 drug Drugs 0.000 description 102
239000010419 fine particle Substances 0.000 description 30
239000000203 mixture Substances 0.000 description 20
230000015572 biosynthetic process Effects 0.000 description 19
238000002156 mixing Methods 0.000 description 17
239000000843 powder Substances 0.000 description 17
238000002664 inhalation therapy Methods 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
239000002552 dosage form Substances 0.000 description 8
210000004072 lung Anatomy 0.000 description 8
230000002829 reductive effect Effects 0.000 description 8
238000005259 measurement Methods 0.000 description 7
230000009466 transformation Effects 0.000 description 7
230000008901 benefit Effects 0.000 description 6
238000003860 storage Methods 0.000 description 6
230000000694 effects Effects 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
238000012545 processing Methods 0.000 description 5
210000002345 respiratory system Anatomy 0.000 description 5
238000001694 spray drying Methods 0.000 description 5
238000010586 diagram Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
239000002178 crystalline material Substances 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000008240 homogeneous mixture Substances 0.000 description 3
-1 hydrates Chemical class 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
229960001664 mometasone Drugs 0.000 description 3
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 3
238000010422 painting Methods 0.000 description 3
230000002028 premature Effects 0.000 description 3
229910001220 stainless steel Inorganic materials 0.000 description 3
239000010935 stainless steel Substances 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
239000000048 adrenergic agonist Substances 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000013461 design Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000011049 filling Methods 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
239000007922 nasal spray Substances 0.000 description 2
238000010951 particle size reduction Methods 0.000 description 2
239000011236 particulate material Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000010079 rubber tapping Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
241001269524 Dura Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010019133 Hangover Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
206010033296 Overdoses Diseases 0.000 description 1
241001330988 Palmyra Species 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229940057282 albuterol sulfate Drugs 0.000 description 1
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
229940125388 beta agonist Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
239000007767 bonding agent Substances 0.000 description 1
230000000572 bronchospasmolytic effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
201000010099 disease Diseases 0.000 description 1
238000004980 dosimetry Methods 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
HVCNNTAUBZIYCG-UHFFFAOYSA-N ethyl 2-[4-[(6-chloro-1,3-benzothiazol-2-yl)oxy]phenoxy]propanoate Chemical compound C1=CC(OC(C)C(=O)OCC)=CC=C1OC1=NC2=CC=C(Cl)C=C2S1 HVCNNTAUBZIYCG-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000009474 immediate action Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical class O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229940125389 long-acting beta agonist Drugs 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
125000003003 spiro group Chemical group 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000930 thermomechanical effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO19994519A 1997-03-20 1999-09-17 Fremgangsmate for fremstilling av agglomerater NO328062B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82112997A	1997-03-20	1997-03-20
PCT/US1998/003799 WO1998041193A1 (en)	1997-03-20	1998-03-16	Preparation of powder agglomerates

Publications (3)

Publication Number	Publication Date
NO994519D0 NO994519D0 (no)	1999-09-17
NO994519L NO994519L (no)	1999-11-19
NO328062B1 true NO328062B1 (no)	2009-11-13

Family

ID=25232603

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19994519A NO328062B1 (no)	1997-03-20	1999-09-17	Fremgangsmate for fremstilling av agglomerater

Country Status (25)

Country	Link
EP (3)	EP1393721B1 (de)
JP (5)	JP3901738B2 (de)
KR (1)	KR100386055B1 (de)
CN (3)	CN100548277C (de)
AR (1)	AR011986A1 (de)
AT (2)	ATE415149T1 (de)
AU (1)	AU741783B2 (de)
CA (3)	CA2706634C (de)
CL (1)	CL2011000050A1 (de)
CZ (1)	CZ295460B6 (de)
DE (2)	DE69840277D1 (de)
DK (2)	DK0969816T3 (de)
ES (2)	ES2316681T3 (de)
HU (2)	HU230274B1 (de)
ID (1)	ID24472A (de)
IL (1)	IL131640A0 (de)
MY (1)	MY120725A (de)
NO (1)	NO328062B1 (de)
NZ (1)	NZ337443A (de)
PL (3)	PL208480B1 (de)
PT (2)	PT1393721E (de)
SK (1)	SK284919B6 (de)
TW (1)	TWI221778B (de)
WO (1)	WO1998041193A1 (de)
ZA (1)	ZA982254B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9723985D0 (en) *	1997-11-14	1998-01-14	Zeneca Ltd	Pharmaceutical compositions
SE9804000D0 (sv)	1998-11-23	1998-11-23	Astra Ab	New composition of matter
SE9804001D0 (sv)	1998-11-23	1998-11-23	Astra Ab	New process
AR022695A1 (es) *	1999-01-28	2002-09-04	Schering Corp	PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
US6623760B1 (en)	1999-01-28	2003-09-23	Schering Corporation	Method of preparing particles for agglomeration
GB9903759D0 (en) *	1999-02-18	1999-04-14	Novartis Ag	Organic compounds
GB9904919D0 (en) *	1999-03-03	1999-04-28	Novartis Ag	Organic compounds
AU6852900A (en) *	1999-08-20	2001-03-19	Norton Healthcare Ltd	Method to produce powders for pulmonary or nasal administration
GB0009605D0 (en) *	2000-04-18	2000-06-07	Glaxo Group Ltd	Medicaments
GB0009609D0 (en) *	2000-04-18	2000-06-07	Glaxo Group Ltd	Therapeutic compositions
GB0009612D0 (en) *	2000-04-18	2000-06-07	Glaxo Group Ltd	Therapeutic formulations
FI20002177A0 (fi) *	2000-10-02	2000-10-02	Orion Yhtymae Oyj	Uusi yhdistelmä astman hoitoon
FI20002215A0 (fi)	2000-10-06	2000-10-06	Orion Yhtymae Oyj	Yhdistelmäpartikkelit
FI20002216A0 (fi)	2000-10-06	2000-10-06	Orion Yhtymae Oyj	Yhdistelmäpartikkelit astman hoitoon
US6667344B2 (en)	2001-04-17	2003-12-23	Dey, L.P.	Bronchodilating compositions and methods
US20030055026A1 (en)	2001-04-17	2003-03-20	Dey L.P.	Formoterol/steroid bronchodilating compositions and methods of use thereof
ITMI20012174A1 (it) *	2001-10-18	2003-04-18	Univ Parma	Polvere per somministrazione nasale di farmaci
US7931022B2 (en)	2001-10-19	2011-04-26	Respirks, Inc.	Method and apparatus for dispensing inhalator medicament
EP1452179A1 (de) *	2003-02-27	2004-09-01	CHIESI FARMACEUTICI S.p.A.	Neue Kombination von hochwirksamer langzeitiger Beta-2-Agonist und einem Corticosteroid
TWI359675B (en)	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
JP2007501194A (ja) *	2003-08-05	2007-01-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ステロイドとβ模倣薬を含む吸入用薬剤
WO2005016111A2 (en)	2003-08-08	2005-02-24	Abgenix, Inc.	Antibodies directed to parathyroid hormone (pth) and uses thereof
US7318925B2 (en)	2003-08-08	2008-01-15	Amgen Fremont, Inc.	Methods of use for antibodies against parathyroid hormone
CA2540005A1 (en) *	2003-09-26	2005-04-07	Schering Corporation	Pulmonary disease treatment
US20070053843A1 (en) *	2003-10-28	2007-03-08	Dawson Michelle L	Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
ATE399536T1 (de) *	2003-12-04	2008-07-15	Pfizer Prod Inc	Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
BRPI0416534A (pt) *	2003-12-04	2007-01-09	Pfizer Prod Inc	composições multiparticuladas com estabilidade melhorada
SE528121C2 (sv) *	2004-03-29	2006-09-05	Mederio Ag	Preparering av torrpulver för på förhand uppmätt DPI
IL168603A (en) *	2005-05-16	2011-05-31	Resdevco Res And Dev Co	Pharmaceutical or cosmetic composition for the prevention and treatment of irritation of mucous cells or skin cells
DE102006030166A1 (de) *	2006-06-29	2008-01-10	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tempern
DE102006053375A1 (de) *	2006-11-10	2008-05-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Mischung von Pulvern
TW201024034A (en)	2008-12-30	2010-07-01	Saint Gobain Abrasives Inc	Bonded abrasive tool and method of forming
US20120101077A1 (en) *	2009-04-24	2012-04-26	Schering Corporation	Agglomerate formulations useful in dry powder inhalers
MX337126B (es)	2009-05-29	2016-02-12	Pearl Therapeutics Inc	Administracion respiratoria de agentes activos.
US8815258B2 (en)	2009-05-29	2014-08-26	Pearl Therapeutics, Inc.	Compositions, methods and systems for respiratory delivery of two or more active agents
GB0918150D0 (en) *	2009-10-16	2009-12-02	Jagotec Ag	Improved formulations
WO2011131663A1 (en) *	2010-04-21	2011-10-27	Chiesi Farmaceutici S.P.A.	"process for providing particles with reduced electrostatic charges"
KR102391332B1 (ko)	2013-03-15	2022-04-26	펄 테라퓨틱스 인코포레이티드	미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템
JP6020489B2 (ja)	2014-02-27	2016-11-02	トヨタ自動車株式会社	昇圧コンバータ及びその制御方法
WO2016067252A1 (en)	2014-10-31	2016-05-06	Glaxosmithkline Intellectual Property Development Limited	Powder formulation
JP7015549B2 (ja) *	2016-01-08	2022-02-03	セロンファーマシューティカルズ，インク	７－アゾニアビシクロ［２．２．１］ヘプタン誘導体の乾燥粉末吸入器組成物
CN117122585A (zh) *	2023-07-27	2023-11-28	宁波诺丁汉大学	一种通过振动混合制备干粉吸入团聚物处方制剂方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1520247A (en)	1974-08-10	1978-08-02	Fisons Ltd	Pelletised medicament formulations
US4161516A (en) *	1975-07-25	1979-07-17	Fisons Limited	Composition for treating airway disease
GB8334494D0 (en)	1983-12-24	1984-02-01	Tanabe Seiyaku Co	Carbostyril derivatives
ES2044710T3 (es) *	1990-01-29	1994-01-01	Ciba Geigy Ag	Procedimiento y dispositivo de dosificacion de un polvo de granulometria fina.
SE9101090D0 (sv) *	1991-04-11	1991-04-11	Astra Ab	Process for conditioning of water-soluble substances
SE9302777D0 (sv) *	1993-08-27	1993-08-27	Astra Ab	Process for conditioning substances
ES2172510T3 (es) *	1991-12-18	2002-10-01	Astrazeneca Ab	Nueva combinacion de formoterol y budesonida.
WO1994014492A2 (en)	1992-12-18	1994-07-07	Schering Corporation	Inhaler for powdered medications
SK283569B6 (sk) *	1993-10-01	2003-09-11	Astra Aktiebolag	Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
IS1736B (is)	1993-10-01	1999-12-30	Astra Ab	Aðferð og tæki sem stuðla að aukinni samloðun agna
PE44995A1 (es) *	1994-01-27	1995-12-18	Schering Corp	Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
CA2206657C (en) *	1994-12-22	2009-05-19	Astra Aktiebolag	Therapeutic preparation for inhalation containing parathyroid hormone, pth

1998
- 1998-03-16 DK DK98911423T patent/DK0969816T3/da active
- 1998-03-16 CN CNB200610099982XA patent/CN100548277C/zh not_active Expired - Lifetime
- 1998-03-16 ES ES03020466T patent/ES2316681T3/es not_active Expired - Lifetime
- 1998-03-16 AU AU65378/98A patent/AU741783B2/en not_active Expired
- 1998-03-16 SK SK1280-99A patent/SK284919B6/sk not_active IP Right Cessation
- 1998-03-16 EP EP03020466A patent/EP1393721B1/de not_active Expired - Lifetime
- 1998-03-16 ID IDW991069A patent/ID24472A/id unknown
- 1998-03-16 EP EP08020312.8A patent/EP2036544B1/de not_active Expired - Lifetime
- 1998-03-16 NZ NZ337443A patent/NZ337443A/en not_active IP Right Cessation
- 1998-03-16 PL PL386407A patent/PL208480B1/pl unknown
- 1998-03-16 ES ES98911423T patent/ES2234102T3/es not_active Expired - Lifetime
- 1998-03-16 DE DE69840277T patent/DE69840277D1/de not_active Expired - Lifetime
- 1998-03-16 PL PL378647A patent/PL204480B1/pl unknown
- 1998-03-16 CA CA2706634A patent/CA2706634C/en not_active Expired - Lifetime
- 1998-03-16 WO PCT/US1998/003799 patent/WO1998041193A1/en not_active Ceased
- 1998-03-16 HU HU0600845A patent/HU230274B1/hu unknown
- 1998-03-16 AT AT03020466T patent/ATE415149T1/de active
- 1998-03-16 CA CA002282360A patent/CA2282360C/en not_active Expired - Lifetime
- 1998-03-16 PL PL335742A patent/PL192441B1/pl unknown
- 1998-03-16 CA CA2481868A patent/CA2481868C/en not_active Expired - Lifetime
- 1998-03-16 JP JP54053098A patent/JP3901738B2/ja not_active Expired - Lifetime
- 1998-03-16 KR KR10-1999-7008578A patent/KR100386055B1/ko not_active Expired - Lifetime
- 1998-03-16 AT AT98911423T patent/ATE284677T1/de active
- 1998-03-16 DE DE69828155T patent/DE69828155T2/de not_active Expired - Lifetime
- 1998-03-16 HU HU0002029A patent/HU226671B1/hu unknown
- 1998-03-16 CZ CZ19993233A patent/CZ295460B6/cs not_active IP Right Cessation
- 1998-03-16 CN CNB988052806A patent/CN1149076C/zh not_active Expired - Lifetime
- 1998-03-16 DK DK03020466T patent/DK1393721T3/da active
- 1998-03-16 EP EP98911423A patent/EP0969816B1/de not_active Expired - Lifetime
- 1998-03-16 IL IL13164098A patent/IL131640A0/xx not_active IP Right Cessation
- 1998-03-16 CN CNB200410032204XA patent/CN100518718C/zh not_active Expired - Lifetime
- 1998-03-16 PT PT03020466T patent/PT1393721E/pt unknown
- 1998-03-16 PT PT98911423T patent/PT969816E/pt unknown
- 1998-03-17 MY MYPI98001155A patent/MY120725A/en unknown
- 1998-03-17 AR ARP980101197A patent/AR011986A1/es not_active Application Discontinuation
- 1998-03-17 ZA ZA982254A patent/ZA982254B/xx unknown
- 1998-03-17 TW TW087103951A patent/TWI221778B/zh not_active IP Right Cessation
1999
- 1999-09-17 NO NO19994519A patent/NO328062B1/no not_active IP Right Cessation
2006
- 2006-03-06 JP JP2006060355A patent/JP2006152000A/ja not_active Withdrawn
2010
- 2010-08-02 JP JP2010174016A patent/JP2010248260A/ja not_active Withdrawn
- 2010-08-02 JP JP2010174015A patent/JP5523240B2/ja not_active Expired - Lifetime
2011
- 2011-01-10 CL CL2011000050A patent/CL2011000050A1/es unknown
2013
- 2013-11-29 JP JP2013247234A patent/JP2014037446A/ja active Pending

Also Published As

Publication number	Publication date
EP0969816A1 (de)	2000-01-12
PT1393721E (pt)	2009-02-02
CN1552310A (zh)	2004-12-08
CA2282360A1 (en)	1998-09-24
AU6537898A (en)	1998-10-12
JP3901738B2 (ja)	2007-04-04
CZ323399A3 (cs)	2000-02-16
JP2006152000A (ja)	2006-06-15
EP1393721A1 (de)	2004-03-03
KR100386055B1 (ko)	2003-06-09
HUP0002029A2 (hu)	2000-11-28
DE69828155T2 (de)	2005-12-22
NO994519D0 (no)	1999-09-17
PL335742A1 (en)	2000-05-08
PL192441B1 (pl)	2006-10-31
AR011986A1 (es)	2000-09-13
JP2010275316A (ja)	2010-12-09
CA2706634C (en)	2012-10-23
CN100518718C (zh)	2009-07-29
TWI221778B (en)	2004-10-11
ES2316681T3 (es)	2009-04-16
CN1149076C (zh)	2004-05-12
CA2481868C (en)	2010-06-15
CN1903179A (zh)	2007-01-31
ID24472A (id)	2000-07-20
HU230274B1 (hu)	2015-11-30
KR20010005520A (ko)	2001-01-15
EP2036544A1 (de)	2009-03-18
CA2481868A1 (en)	1998-09-24
DE69840277D1 (de)	2009-01-08
NZ337443A (en)	2001-04-27
CA2706634A1 (en)	1998-09-24
DK0969816T3 (da)	2005-03-14
PT969816E (pt)	2005-04-29
ZA982254B (en)	1998-09-17
DE69828155D1 (de)	2005-01-20
HK1061359A1 (en)	2004-09-17
HU226671B1 (en)	2009-06-29
CN1257423A (zh)	2000-06-21
CL2011000050A1 (es)	2011-06-24
JP2000510478A (ja)	2000-08-15
IL131640A0 (en)	2001-01-28
ATE415149T1 (de)	2008-12-15
HU0600845D0 (en)	2007-01-29
SK128099A3 (en)	2000-06-12
ATE284677T1 (de)	2005-01-15
CA2282360C (en)	2004-11-09
AU741783B2 (en)	2001-12-06
CZ295460B6 (cs)	2005-08-17
HK1021323A1 (en)	2000-06-09
WO1998041193A1 (en)	1998-09-24
JP2014037446A (ja)	2014-02-27
EP1393721B1 (de)	2008-11-26
EP2036544B1 (de)	2016-12-28
JP2010248260A (ja)	2010-11-04
HUP0002029A3 (en)	2001-02-28
MY120725A (en)	2005-11-30
JP5523240B2 (ja)	2014-06-18
PL204480B1 (pl)	2010-01-29
CN100548277C (zh)	2009-10-14
SK284919B6 (sk)	2006-02-02
NO994519L (no)	1999-11-19
DK1393721T3 (da)	2009-03-30
PL208480B1 (pl)	2011-05-31
ES2234102T3 (es)	2005-06-16
EP0969816B1 (de)	2004-12-15

Legal Events

Date

Code

Title

Description

2012-09-24

CHAD

Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

2018-04-09

MK1K

Patent expired

Publication	Publication Date	Title
NO328062B1 (no)	2009-11-13	Fremgangsmate for fremstilling av agglomerater
US7687073B2 (en)	2010-03-30	Preparation of powder agglomerates
US8173172B2 (en)	2012-05-08	Preparation of powder agglomerates
HK1021323B (en)	2005-06-03	Preparation of powder agglomerates
HK1061359B (en)	2009-03-06	Dosage form of powder agglomerates
HK1122747A (en)	2009-05-29	Dosage form of powder agglomerates
MXPA99008581A (en)	2000-02-02	Preparation of powder agglomerates